Quantcast

Latest Timolol Stories

2010-09-07 07:50:00

MORRISTOWN, N.J., Sept. 7 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc. filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution, 0.2%/0.5%. Watson's Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution, 0.2%/0.5% is a generic version of Allergan Inc.'s...

2010-03-09 09:30:00

LAWRENCEVILLE, N.J., March 9 /PRNewswire/ -- Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced that it has launched an authorized generic version of its Timoptic-XE® (timolol maleate ophthalmic gel forming solution). Timoptic-XE is a non-selective beta-adrenergic receptor blocking agent indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Aton also announced that it will...

2010-03-04 10:28:00

LAWRENCEVILLE, N.J., March 4 /PRNewswire/ -- Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced that in an independent survey of U.S. ophthalmologists by Frost & Sullivan, Timoptic® was rated the leading brand name of beta blockers for glaucoma. Timoptic received Frost & Sullivan's 2010 Best Practices Award as the "Best Brand Name of Beta Blockers for Glaucoma," based on its Brand Perception Index (BPI) score, reflecting strong...

2010-02-01 19:00:00

IRVINE, Calif., Feb. 1 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA) today announced it had exceeded the $100 million revenue threshold with preliminary, unaudited net revenues of $110.6 million for the year ended December 31, 2009. ISTA's continued growth of its Xibrom(TM) (bromfenac ophthalmic solution) 0.09% and Istalol® (timolol maleate ophthalmic solution) 0.5% franchises, in addition to initial orders for ISTA's recently approved treatment...

2009-08-19 09:00:00

LAWRENCEVILLE, N.J., Aug. 19 /PRNewswire/ -- Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced it has launched new education, distribution, sampling and reimbursement programs for TIMOPTIC(R) in OCUDOSE(R), the only preservative-free medication for glaucoma available in the United States. Aton acquired the U.S. marketing rights in February to the TIMOPTIC product line from Merck & Co., Inc. TIMOPTIC (timolol maleate) is a non-selective beta-adrenergic...

2009-06-30 10:47:00

Award Recognizes Entrepreneurial Excellence LAWRENCEVILLE, N.J., June 30 /PRNewswire/ -- Aton Pharma, Inc. announced today that its Chief Executive Officer, Michael G. Wells, has received the Ernst & Young Entrepreneur Of The Year(R) 2009 Award in the emerging companies category in New Jersey. According to Ernst & Young LLP, the award recognizes outstanding entrepreneurs who are building and leading dynamic, growing businesses. Mr. Wells was selected by an independent panel of...

2009-04-06 08:00:00

LAWRENCEVILLE, N.J., April 6 /PRNewswire/ -- In a recent survey of ophthalmologists across the nation, virtually all (97%) believe preservative-free glaucoma medications can enhance the ocular comfort of glaucoma patients, while 86% believe that preservative-free glaucoma medications can enhance patient quality of life. Nine out of ten (89%) feel there are not enough preservative-free glaucoma medications available, and nearly half (47%) do not know a preservative-free beta-blocker is...

2009-02-25 08:00:00

LAWRENCEVILLE, N.J., Feb. 25 /PRNewswire/ -- Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced it has acquired the U.S. marketing rights to the TIMOPTIC(R) product line from Merck & Co., Inc. TIMOPTIC (timolol maleate) is a non-selective beta-adrenergic receptor blocking agent indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. As many as 2.25 million Americans suffer from open-angle...

2008-10-30 09:00:40

Hi-Tech Pharmacal, a specialty pharmaceutical company, has announced that the FDA has granted final approval to the company's abbreviated new drug application for dorzolamide and timolol ophthalmic solution, the generic for Merck's Cosopt. The product is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta blockers. Hi-Tech plans to launch generic dorzolamide and timolol ophthalmic...

2008-09-16 09:00:53

Othera Pharmaceuticals, a specialty pharmaceutical company, has initiated dosing in a Phase I/II clinical trial to determine the safety and efficacy of topical OT-730 in patients with ocular hypertension and glaucoma. The study is a randomized, multi-center, investigator-masked, timolol- and placebo-controlled evaluation of the safety and efficacy of OT-730 in reducing the intraocular pressure in subjects with ocular hypertension or open-angle glaucoma. Subjects will be randomized to one of...


Word of the Day
humgruffin
  • A terrible or repulsive person.
Regarding the etymology of 'humgruffin,' the OED says (rather unhelpfully) that it's a 'made-up word.' We might guess that 'hum' comes from 'humbug' or possibly 'hum' meaning 'a disagreeable smell,' while 'gruffin' could be a combination of 'gruff' and 'griffin.'